SubsidieMeestersEDV2209 – a Paradigm shift in the treatment of stroke.
Edvince aims to revolutionize stroke treatment with its innovative drug EDV2209, enhancing cerebral blood flow to prevent brain damage from severe subarachnoid hemorrhage.
Projectdetails
Introduction
Despite tremendous research efforts and a large number of clinical trials focused on developing treatments for stroke, the field's current state remains dismal. There are, at present, no efficient treatments nor promising drug candidates for this lethal and disabling condition.
Need for New Approaches
A different perspective with a new approach is therefore desperately needed. Edvince's drug discovery and development is born out of founder and Professor Lars Edvinsson's extensive, fundamental, and pioneering research of cerebral circulation, receptor regulation, stroke, and migraines.
Clinical Trial Plans
Edvince is now ready to conduct the first clinical trial in 2022 with its innovative and disruptive lead drug EDV2209, an orphan drug for the treatment of brain ischemia associated with severe subarachnoid hemorrhage (SAH).
Mechanism of Action
The drug helps to keep the blood vessels in the brain open, allowing brain cells to receive oxygen and nutrients to prevent brain damage.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 4.422.831 |
Tijdlijn
| Startdatum | 1-1-2022 |
| Einddatum | 31-10-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- EDVINCE AKTIEBOLAGpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
BraiN20®: A paradigm shift in Acute Ischemic Stroke (AIS) patient managementBraiN20 is a non-invasive device that monitors brain viability in AIS patients to enhance EVT decision-making and improve treatment outcomes through real-time data. | EIC Accelerator | € 2.500.000 | 2023 | Details |
ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)The project aims to conduct a Phase 2b trial of ApTOLL, a novel neuroprotectant for acute ischemic stroke, to reduce brain damage and improve outcomes, targeting a multi-billion euro market. | EIC Accelerator | € 2.498.816 | 2024 | Details |
NAO.VNS: A New Personalized Neural Stimulation Therapy For Drug-resistant EpilepsyNAO.VNS is an innovative implantable vagus nerve stimulator using optical fibers to enhance treatment for drug-resistant epilepsy, enabling personalized therapy and remote monitoring, with market approval expected by 2028. | EIC Accelerator | € 2.499.000 | 2023 | Details |
Brain Interchange ONE SR—the implantable neuromodulation technology for stroke rehabilitationCorTec aims to develop innovative implantable technology for stroke rehabilitation, enabling new therapies and devices while targeting market approval and $250M in sales by 2030. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Paradigm shift in stroke: accurate diagnosis and evaluation of all treatment options in any hospital, at any timeMethinks aims to transform stroke diagnosis by enabling all hospitals to evaluate treatment options using standard imaging, reducing time-to-treatment and improving patient outcomes globally. | EIC Accelerator | € 2.495.415 | 2023 | Details |
BraiN20®: A paradigm shift in Acute Ischemic Stroke (AIS) patient management
BraiN20 is a non-invasive device that monitors brain viability in AIS patients to enhance EVT decision-making and improve treatment outcomes through real-time data.
ApTOLL: An innovative neuroprotectant to reduce brain damage in Acute Ischemic Stroke (AIS)
The project aims to conduct a Phase 2b trial of ApTOLL, a novel neuroprotectant for acute ischemic stroke, to reduce brain damage and improve outcomes, targeting a multi-billion euro market.
NAO.VNS: A New Personalized Neural Stimulation Therapy For Drug-resistant Epilepsy
NAO.VNS is an innovative implantable vagus nerve stimulator using optical fibers to enhance treatment for drug-resistant epilepsy, enabling personalized therapy and remote monitoring, with market approval expected by 2028.
Brain Interchange ONE SR—the implantable neuromodulation technology for stroke rehabilitation
CorTec aims to develop innovative implantable technology for stroke rehabilitation, enabling new therapies and devices while targeting market approval and $250M in sales by 2030.
Paradigm shift in stroke: accurate diagnosis and evaluation of all treatment options in any hospital, at any time
Methinks aims to transform stroke diagnosis by enabling all hospitals to evaluate treatment options using standard imaging, reducing time-to-treatment and improving patient outcomes globally.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Personalised Health cognitive assistance for RehAbilitation SystEmPHRASE aims to enhance stroke rehabilitation through personalized intervention protocols, leveraging advanced technology and expert collaboration to improve patient outcomes and reduce economic burdens. | EIC Transition | € 2.496.674 | 2022 | Details |
Monitoring of stroke patients with 3D ultrasound localization microscopyThe ERC POC StrokeMonitor project aims to validate a portable super-resolution ultrasound device for monitoring delayed cerebral ischemia in stroke patients, enhancing neuroimaging accessibility and accuracy. | ERC Proof of... | € 150.000 | 2023 | Details |
The pursuit of non-invasive treatment for intracranial aneurysms to PRevent aneurYSMal subarachnoid hemorrhageThe Treat-PRYSM project aims to validate and repurpose five candidate drugs to prevent aSAH in unruptured intracranial aneurysms by targeting the EndMT and TGF- pathways, with a focus on sex-specific effects. | ERC Proof of... | € 150.000 | 2025 | Details |
Advancing stroke care with cutting-edge ultrasound biomarkers for Neurocritical CareResolve Stroke aims to enhance ultrasound imaging with the SYLVER system to improve stroke diagnosis and management through innovative biomarkers, making timely detection more accessible and effective. | EIC Transition | € 2.493.436 | 2025 | Details |
Drug DELIvery to the brain via CHOroid Plexus targetingThis project aims to explore the blood-CSF barrier as a novel route for delivering therapeutics to the brain, potentially enhancing treatment strategies for CNS disorders. | ERC Consolid... | € 1.999.756 | 2024 | Details |
Personalised Health cognitive assistance for RehAbilitation SystEm
PHRASE aims to enhance stroke rehabilitation through personalized intervention protocols, leveraging advanced technology and expert collaboration to improve patient outcomes and reduce economic burdens.
Monitoring of stroke patients with 3D ultrasound localization microscopy
The ERC POC StrokeMonitor project aims to validate a portable super-resolution ultrasound device for monitoring delayed cerebral ischemia in stroke patients, enhancing neuroimaging accessibility and accuracy.
The pursuit of non-invasive treatment for intracranial aneurysms to PRevent aneurYSMal subarachnoid hemorrhage
The Treat-PRYSM project aims to validate and repurpose five candidate drugs to prevent aSAH in unruptured intracranial aneurysms by targeting the EndMT and TGF- pathways, with a focus on sex-specific effects.
Advancing stroke care with cutting-edge ultrasound biomarkers for Neurocritical Care
Resolve Stroke aims to enhance ultrasound imaging with the SYLVER system to improve stroke diagnosis and management through innovative biomarkers, making timely detection more accessible and effective.
Drug DELIvery to the brain via CHOroid Plexus targeting
This project aims to explore the blood-CSF barrier as a novel route for delivering therapeutics to the brain, potentially enhancing treatment strategies for CNS disorders.